NKGen Biotech administers first dose of troculeucel for FTD under FDA-cleared compassionate use

Pallavi Madhiraju- February 23, 2025 0

NKGen Biotech, Inc. (Nasdaq: NKGN), a clinical-stage biotechnology company specializing in natural killer cell therapy, has taken a significant step in the treatment of frontotemporal ... Read More

Biogen’s SKYCLARYS becomes first approved treatment for Friedreich’s Ataxia in EU

Pallavi Madhiraju- February 13, 2024 0

In a landmark decision, the European Commission (EC) has authorized Biogen Inc.'s SKYCLARYS (omaveloxolone) for the treatment of Friedreich’s ataxia (FA) in adults and adolescents ... Read More

Biohaven secures orphan drug status for verdiperstat in MSA treatment

pharmanewsdaily- February 20, 2019 0

Connecticut-based Biohaven Pharmaceutical has received a significant regulatory boost, with the US FDA granting orphan drug designation for its investigational drug verdiperstat for treating multiple ... Read More